跳至主要内容
临床试验/ACTRN12610000874011
ACTRN12610000874011已完成2 期

An investigator blinded controlled study of the nasal application of 5% tea tree oil (TTO) versus mupirocin for the prevention of catheter-associated infections in renal dialysis patients

The University of Western Australia0 个研究点目标入组 100 人开始时间: 2010年10月18日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Haemodialysis or peritoneal dialysis planned

排除标准

  • Known sensitivity to tea tree oil
  • Use of medicated and non-medicated nasal ointments in the past 12 weeks
  • Serious, uncontrolled disease (including serious psychological disorders) likely to interfere with the study and/or likely to cause death within the study duration
  • Acute renal failure

研究者

相似试验

进行中(未招募)
1 期
Clinical trial MV-CHIK-205 is designed to investigate the safety, tolerability, and long-term immunogenicity of a novel vaccine designed to protect against chikungunya virus, a mosquito-borne pathogen causing chikungunya fever throughout tropical areas worldwide.The study is being conducted in healthy volunteers for the prophylaxis of chikungunya virus (CHIKV) infection.
EUCTR2018-000211-25-GBThemis Bioscience GmbH60
进行中(未招募)
不适用
A randomised assessor blinded study to examine the role of skin testing in the prediction of peri-operative anaphylaxis and its correlation with mast cell tryptase and total IgE. - Peri-operative screening for sensitization to NMDAsPrevalance of sensitivity of immune system to the four named neuromuscular blocking drugs in patients undergoing anaesthesia.
EUCTR2005-001622-91-GBRoyal Group Hospitals160
进行中(未招募)
不适用
An Investigator-blind, Controlled Study to Assess the Efficacy of Five Distinct Combinations of LAS 41004 in Different Concentrations Compared to Placebo and to Two Active Controls in a Psoriasis-Plaque-Test
EUCTR2010-018355-10-DEAlmirall Hermal GmbH
进行中(未招募)
不适用
An Investigator-blind, Controlled Study to Assess the Efficacy and Safety of different formulations of LAS 41004 Compared to Placebo and to Active Control in a Psoriasis-Plaque-Test
EUCTR2010-022281-27-DEAlmirall Hermal GmbH
进行中(未招募)
不适用
Efficacy and Safety of different formulations of LAS 41004 compared to active control and placeboPlaque-type psoriasis (psoriasis vulgaris) for at least 12 monthsMedDRA version: 13.1Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disorders
EUCTR2011-000186-13-DEAlmirall Hermal GmbH